lowers All-cause mortality
Regular glucosamine use was associated with significantly lower all-cause, cardiovascular, cancer, respiratory and digestive mortality (all-cause HR 0.73).
Annals of the Rheumatic Diseases, 2020 · PubMed 32253185
D-Glucosamine, graded Moderate-evidence on Magellan — the UK Biobank mortality association (HR ~0.85) is observational and has drawn published selection/healthy-user-bias critiques—longevity benefit is unproven. Studied dose: ~1,500 mg/day (sulfate). Magellan links 24 peer-reviewed citations for D-Glucosamine. D-Glucosamine sulfate is a salt of glucosamine, an amino monosaccharide the body synthesizes from glucose and uses as a building block for the glycosaminoglycans and proteoglycans that make up joint cartilage.
Source: Annals of the Rheumatic Diseases 2020, PMID 32253185 ↗ · Evidence-graded supplements · Research map · Study write-up · evidence confidence: high
D-Glucosamine, an amino-sugar used for joint health, acts as a calorie-restriction mimetic — activating AMPK via the hexosamine pathway — and regular use is linked in large human cohorts to lower all-cause and cardiovascular mortality.
Energy-restriction mimetic; activates AMPK via the hexosamine pathway. Linked to lower mortality.
Regular glucosamine use was associated with significantly lower all-cause, cardiovascular, cancer, respiratory and digestive mortality (all-cause HR 0.73).
Annals of the Rheumatic Diseases, 2020 · PubMed 32253185
Higher genetically predicted glucosamine was associated with greater odds of extended parental lifespan, consistent with a causal effect on longevity.
Mendelian Randomization study, 2022 · PubMed 35623867
Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort.
Frontiers in Pharmacology (NHANES), 2020 · PubMed 33219063
Curated supplements. Links are affiliate (Amazon Associates, tag magellanlong-20) — we may earn a commission at no cost to you.
D-Glucosamine, an amino-sugar used for joint health, acts as a calorie-restriction mimetic — activating AMPK via the hexosamine pathway — and regular use is linked in large human cohorts to lower all-cause and cardiovascular mortality.
Regular glucosamine use was associated with significantly lower all-cause, cardiovascular, cancer, respiratory and digestive mortality (all-cause HR 0.73).
Higher genetically predicted glucosamine was associated with greater odds of extended parental lifespan, consistent with a causal effect on longevity.
Glucosamine/chondroitin use was associated with reduced all-cause mortality in a nationally representative U.S. cohort.